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Abstract
We previously reported that acylphosphatase, a cytosolic enzyme present in skeletal and heart muscle, actively hydrolyzes the
phosphoenzyme (EP) of cardiac sarcoplasmic reticulum (SR) Ca2þ-ATPase (SERCA2a), inducing an increased activity of this
pump. We hypothesized that acylphosphatase-induced stimulation of SERCA2a, in addition to enhanced EP hydrolysis, may be due
to a displacement of phospholamban (PLN), removing its inhibitory effect. To verify this hypothesis co-immunoprecipitation ex-
periments were performed by adding recombinant muscle acylphosphatase to solubilized heart SR vesicles, used as a source of
SERCA2a and PLN. With anti-acylphosphatase antibodies only SERCA2a was co-immunoprecipitated in an amount which in-
creased in parallel to the concentrations of our enzyme. Conversely, using anti-SERCA2a antibody, both PLN and acylphosphatase
were co-immunoprecipitated with SERCA2a, and the PLN amount in the precipitate decreased with increasing acylphosphatase
concentrations. SERCA2a and PLN were co-immunoprecipitated by anti-phospholamban antibodies, but while the amount of
precipitated phospholamban increased in the presence of acylphosphatase, the level of SERCA2a decreased. These preliminary
results strengthen the supposed displacement of phospholamban by acylphosphatase.
 2003 Elsevier Science (USA). All rights reserved.
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Sarco(endo)plasmic reticulum Ca2þ-ATPases (SER-
CAs) are 110-kDa transmembrane proteins that trans-
port Ca2þ ions from the sarcoplasm to the lumen of the
membrane system [1]. The energy for Ca2þ transport is
provided by ATP; intermediate steps involve the forma-
tion and hydrolysis of a phosphoenzyme intermediate
(EP) [2]. The cardiac sarcoplasmic reticulum (SR) Ca2þ-
ATPase (SERCA2a) is regulated by its interactions with
the intrinsic membrane protein phospholamban. Phos-
pholamban (PLN) inhibits the activity of SERCA2a, but
its phosphorylation by protein kinase A or Ca2þ-cal-
modulin kinase reverses the inhibitory interaction, pre-
sumably through dissociation of phosphorylated
phospholamban from SERCA2a [3]. An additional reg-
ulatory effect on SERCA2a could be exerted by acyl-
phosphatase (EC 3.6.1.7), a cytosolic 11 kDa enzyme well
represented in cardiac muscle that catalyzes the hydro-
lysis of acylphosphates [4–6]. In previous studies we have
shown that acylphosphatase actively hydrolyzes the EP
intermediate of this transport system, an effect that results
in an enhanced activity of the SR Ca2þ pump [7,8]. We
have also demonstrated that acylphosphatase, in addi-
tion to its hydrolytic activity on EP, stimulated SER-
CA2a activity through another mechanism, probably due
to its conformational properties. In fact, using an acyl-
phosphatase mutant, Asn41Ser, devoid of catalytic ac-
tivity but unchanged as for the three-dimensional
structure [9], the stimulatory effect on SERCA2a was
retained, but disappeared when the conformational
structure of the mutant was altered by thermal denatur-
ation. To explain these results we supposed that acyl-
phosphatase could interact with SERCA2a taking the
place of unphosphorylated PLN whose inhibitory effect
could be removed [8]. In fact, NMR studies showed that
acylphosphatase contains a structural motif where 12
residues (from 55 to 66) form an amphipathic a-helix with
a prevalence of basic groups [10] that resembles that of
the PLN cytoplasmic 1A domain, essential for the asso-
ciation with SERCA2a [11].
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In the present study, as a first approach to verify the
supposed interaction, we performed a series of co-
immunoprecipitation experiments. Mixtures of solubi-
lized cardiac SR vesicles, used as a source of SERCA2a
and PLN, and recombinant muscle acylphosphatase
were incubated with antibodies against each of these
proteins and the composition of the obtained immuno-
precipitates was determined by Western blot analysis.
Materials and methods
Materials. All reagents were of analytical grade and were obtained
from Sigma. Monoclonal (mouse) anti-SERCA2a ATPase antibody
(clone 2A7-A1) was obtained from Affinity Bioreagents (Golden, CO),
monoclonal (mouse) anti-phospholamban antibody (clone A1) was
from Upstate biotechnology (Lake Placid, NY), and acylphosphatase
recombinant form was obtained according to Modesti et al. [12].
Anti-acylphosphatase antibodies were raised in rabbit using the
recombinant protein and purified by affinity chromatography [13].
Peroxidase coniugated anti-mouse or anti-rabbit secondary antibody
was from Amersham. Super Signal enhanced chemiluminescent kit was
from Pierce.
Preparation of SR vesicles (SRVs). Cardiac SRVs were isolated
from rabbit heart according to Nediani et al. [14] and measured for
protein [15].
Co-immunoprecipitation. SRVs were solubilized with 1% SDS in the
immunoprecipitation buffer (10mM Tris–HCl, pH 7, 150mM NaCl,
1mM EGTA, and 1mM EDTA) at room temperature for 1 h and
centrifuged for 150 at 16,000g. The supernatants were rotated with 1%
bovine serum albumin-treated G-Sepharose for 300 and centrifuged to
remove proteins bound non-specifically to G-Sepharose. The super-
natants, at a final concentration of 0.5mg/ml protein, were then
incubated with monoclonal anti-SERCA2a or polyclonal anti-acyl-
phosphatase or monoclonal anti-PLN antibody in the absence and in
the presence of 5 or 10 lg of acylphosphatase recombinant form on ice
for 1 h. The samples were rotated for 1 h with G-Sepharose and cen-
trifuged and the pellets were washed three times in the immunopre-
cipitation buffer and solubilized for 100 at 90 C in Laemmlis sample
buffer [16].
Western blot analysis of SERCA2a, phospholamban, and acylphos-
phatase. Samples were resolved by 10% and 15% SDS–PAGE and
transferred to PVDF membranes. After blocking, the membrane were
incubated with monoclonal anti-SERCA2a, or polyclonal anti-human
muscle acylphosphatase or monoclonal anti-PLB antibody, washed
three times in T-TBS solution (50mM Tris–HCl, pH 7.4, 150mM
NaCl, and 0.1% Tween 20), and treated with horseradish peroxidase-
conjugated anti-mouse or anti-rabbit secondary antibody. The signals
were detected with a chemiluminescence kit and the signal densities
corresponding to SERCA2a or PLN immunoprecipitated were quan-
tified by laser densitometry using Quantity One software (Bio-Rad
laboratories).
Results and discussion
Taken together, the results of this study agree with
the possibility that acylphosphatase, owing to its con-
formational properties, displaces PLN from SERCA2a.
In this connection, we have previously demonstrated a
physical interaction between SERCA2a and acylphos-
phatase since in controlled immunoprecipitation exper-
iments the two proteins were co-precipitated by a
monoclonal anti-SERCA2a antibody. In the same
study, however, we found that thermally denaturated
acylphosphatase was not more precipitated, suggesting
that the maintenance of the native conformation of this
enzyme was required for its binding to SERCA2a [8].
Now, in addition to confirming a physical association
between SERCA2a and acylphosphatase, the present
results also indicate that this binding could interfere
with SERCA2a–PLN interaction. This, at least, emerges
from the experiments that we performed by incubating
SERCA2a and PLN (in the form of solubilized cardiac
SR vesicles) with monoclonal anti-SERCA2a antibody
in the absence and in the presence of increasing amounts
of purified recombinant acylphosphatase. As shown in
the Fig. 1A, when acylphosphatase was lacking Western
blot analysis of the immunoprecipitate revealed two
clear bands at 110 kDa and 25–27 kDa, corresponding,
respectively, to SERCA2a and to the PLN pentameric
form: a result which was expected since the well-known
interaction between these proteins. On the other hand,
in the presence of acylphosphatase, the analysis of the
immunoprecipitate showed another band at 11 kDa,
suggesting the co-immunoprecipitation of this enzyme
together with the other two proteins. Moreover, as
Fig. 1. Effect of acylphosphatase (ACP) on co-immunoprecipitation of
SERCA2a with PLN using monoclonal anti-SERCA2a antibody.
Solubilized SRVs were incubated with monoclonal anti-SERCA2a
antibody as described under ‘‘Materials and methods’’ in the absence
(0) and in presence of 5 or 10 lg of ACP. Immunoprecipitates were
analyzed by Western blotting (A) and PLN signals were quantified by
densitometric analysis (B). Each bar represents the mean value SD of
four different blots. *p < 0:05 vs 0 by Students t test.
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indicated by densitometric analysis (Fig. 1B), the
amount of PLN found in the immunoprecipitated sig-
nificantly decreased with increasing acylphosphatase
concentrations, with a diminution that, compared to the
control values, was 17% for the lower (5 lg) and 37% for
the higher acylphosphatase levels (10 lg). Besides these
findings that clearly strengthen the supposed displace-
ment of phospholamban by acylphosphatase, also other
results of the present study support such an interpreta-
tion. In fact, when the above described mixtures of
solubilized heart SR vesicles plus acylphosphatase were
added with anti-acylphosphatase antibody (Fig. 2A)
only this enzyme and SERCA2a were co-immunopre-
cipitated and the amount of SERCA2a detected in the
precipitate increased significantly with the increase in
acylphosphatase concentration. While, on one hand,
these data corroborate the view of a selective interaction
between acylphosphatase and SERCA2a, on the other
hand the constant absence of PLN in the immunopre-
cipitate obtained with anti-acylphosphatase antibody
strongly suggests that acylphosphatase, through a sort
of competitive binding with SERCA2, can effectively
displace PLN from its association with heart SR Ca2þ
pump. Also the results obtained with monoclonal anti-
phospholamban antibody agree with this conclusion. In
fact, as shown in the Fig. 3, the amount of SERCA2a,
which was co-immunoprecipitated with PLN by this
antibody, was markedly reduced when 10 lg of acyl-
phosphatase was added to the reaction mixture. The
presence of acylphosphatase also resulted in an in-
creased amount of PLN in the precipitate; a finding that
may be explained admitting, as suggested by other au-
thors [17], that the interaction with SERCA2a prevents,
to a certain extent, PLN from reaching with its
own antibody: this hindrance could be removed in
consequence of the displacement produced by acyl-
phosphatase. Much attention has been directed to
SERCA2a–PLN interactions which, by affecting intra-
cellular Ca2þ homeostasis, play a key role in the regu-
lation of cardiac contractility and relaxation [2,3,17]. In
this regard, recent studies reported that overexpression
of a superinhibitory PLN mutant induces cardiac hy-
pertrophy in mouse, impairing contractility and relaxa-
tion of heart muscle [18,19]; on the contrary, PLN
ablation or overexpression of SERCA2a mutant lacking
the functional association with PLN resulted in both
Fig. 2. Co-immunoprecipitation of SERCA2a and acylphosphatase
(ACP) with polyclonal anti-ACP antibody. Solubilized SRVs were
incubated with polyclonal anti-ACP antibody as described under
‘‘Materials and methods’’ in the presence of 5 and 10lg of ACP.
Immunoprecipitates were analyzed by Western blotting (A) and
SERCA2a signals were quantified by densitometric analysis (B). Each
bar represents the mean value SD of four different blots. *p < 0:05 vs
5 lg by Students t test.
Fig. 3. Effect of acylphosphatase (ACP) on co-immunoprecipitation of
SERCA2a with PLN using monoclonal anti-PLN antibody. Solubi-
lized SRVs were incubated with monoclonal anti-SERCA2a antibody
as described under ‘‘Materials and methods’’ in the absence (0) and in
the presence of 10 lg of ACP. Immunoprecipitates were analyzed by
Western blotting (A) and SERCA2a and PLN signals were quantified
by densitometric analysis (B). Each bar represents the mean
valueSD of four different blots. , (0); , 10 lg of ACP. *p < 0:05
vs 0 by Students t test.
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attenuation of cardiac hypertrophy and enhancement of
cardiac contractility in a mouse dilated cardiomyopathy
model [20] and in a mice pressure-overload model [21],
suggesting that the removal of PLN inhibition on
SERCA2a may be a new strategy to treat and to prevent
heart failure. In this context it is our opinion that, al-
though preliminary, the present data may be of special
interest because they suggest a novel physiological
mechanism which could contribute to modulate SER-
CA–PLN interactions, all the more so since in a recent
study we found that, in a model of volume overload,
increased acylphosphatase expression was associated to
a recovery of SR function and an improved heart con-
tractility [22].
On the basis of these considerations we think that it
would be of interest to probe more deeply the molecular
basis of the interaction between SERCA2a and acyl-
phosphatase. More in particular, further studies will be
aimed, in our intention, at identifying the residues that
are involved in this interaction and to determine, with
site-specific mutagenesis, the mutations that could cause
a loss of the native conformation of acylphosphatase
and a reduction of its hypothesized displacement effect.
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